Iain Walters

USPTO Granted Patents = 27 (Patent Applications = 3)

CIPO Patents = 3 (Patent Applications = 2)

EPO Patents = 13 (Patent Applications = 15)

Average Co-Inventor Count = 3.7

ph-index = 10

Forward Citations = 334(Granted Patents)

Location History:

Charnwood, GB (2006)
Loughborough, GB (2005 - 2021)
Nottingham, GB (2014 - 2023)

Company Filing History:

15 out of 130

Corcept Therapeutics Incorporated

Years Active: 2005-2025

Loading Chart...

27 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12226412 - Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators (2025-02-18),

2. 12139486 - Octahydro fused azadecalin glucocorticoid receptor modulators (2024-11-12),

3. 11648245 - Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators (2023-05-16),

4. 11576907 - Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators (2023-02-14),

5. 11560379 - Octahydro fused azadecalin glucocorticoid receptor modulators (2023-01-24),

6. 11370789 - Octahydro fused azadecalin glucocorticoid receptor modulators (2022-06-28),

7. 11208381 - Indole derivatives and their use as protein kinase inhibitors (2021-12-28),

8. 11142515 - Pyrazolyl-ureas as kinase inhibitors (2021-10-12),

9. 11046672 - Indolinones compounds and their use in the treatment of fibrotic diseases (2021-06-29),

10. 10973813 - Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators (2021-04-13),

11. 10787449 - Octahydro fused azadecalin glucocorticoid receptor modulators (2020-09-29),

12. 10669235 - Indole derivatives and their use as protein kinase inhibitors (2020-06-02),

13. 10456392 - Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators (2019-10-29),

14. 10323034 - Octahydro fused azadecalin glucocorticoid receptor modulators (2019-06-18),

15. 10294216 - Pyrazolyl ureas as kinase inhibitors (2019-05-21),

Title: The Innovative Journey of Inventor Iain Walters

Introduction: Iain Walters, an accomplished inventor based in Nottingham, GB, has made significant contributions to the field of pharmaceuticals, holding an impressive portfolio of 27 patents. His work primarily focuses on developing novel compounds that serve as glucocorticoid receptor modulators, showcasing his commitment to advancing medical science.

Latest Patents: Among his latest innovations are two noteworthy patents:

1. **Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators** - This invention presents heteroaryl ketone fused azadecalin compounds, along with methods for their use as glucocorticoid receptor modulators. Importantly, these compounds have potential applications in treating amyotrophic lateral sclerosis (ALS).

2. **Octahydro fused azadecalin glucocorticoid receptor modulators** - This patent provides details on octahydro fused azadecalin compounds and outlines methods for employing these compounds as glucocorticoid receptor modulators.

Career Highlights: Iain has worked with leading companies in the pharmaceutical industry, such as Corcept Therapeutics Incorporated and AstraZeneca AB. His affiliations with these organizations demonstrate his crucial role in pioneering innovative solutions in drug development.

Collaborations: Throughout his career, Iain has collaborated with notable colleagues, including Hazel Joan Hunt and Tony Johnson. These partnerships have likely contributed to the enhancement and expansion of his inventive projects.

Conclusion: Iain Walters exemplifies the spirit of innovation in the pharmaceutical realm. With a strong track record of patents focused on glucocorticoid receptor modulators, he stands as a testament to the potential of inventive minds in shaping the future of medicine. His ongoing contributions continue to inspire and influence the healthcare landscape.

This text is generated by artificial intelligence and may not be accurate.